Amneal Pharmaceuticals, Inc. - News - Press Releases

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002

Nov 19, 2021

Amneal Receives Approval for Difluprednate Ophthalmic Emulsion

Nov 12, 2021

Amneal to Virtually Participate at Upcoming Investor Conferences

Nov 03, 2021

Amneal Reports Third Quarter 2021 Financial Results

Nov 02, 2021

Amneal Releases Inaugural Corporate Responsibility Report Highlighting Our Impact as a Socially Responsible Company

Oct 27, 2021

Amneal Launches Generic Dexamethasone Following ANDA Approval by FDA

Oct 06, 2021

Amneal to Report Third Quarter 2021 Results on November 3, 2021

Sep 07, 2021

Amneal to Virtually Participate at Morgan Stanley 19th Annual Global Healthcare Conference

Aug 25, 2021

Amneal Announces Positive Topline Results from Pivotal Phase 3 RISE-PD Clinical Trial of IPX-203 in Patients with Parkinson’s Disease Who Experience Motor Fluctuations

Aug 23, 2021

Amneal Announces Virtual Event to Discuss Initial Data from Pivotal Phase 3 Study of IPX-203 in Patients with Parkinson’s Disease Who Experience Motor Fluctuations

Aug 09, 2021

Amneal Reports Second Quarter 2021 Financial Results

Jul 19, 2021

Amneal Receives Approval for Generic TobraDex®

Jul 15, 2021

Amneal to Report Second Quarter 2021 Results on August 9, 2021

Jun 17, 2021

Amneal Announces U.S. FDA Filing Acceptance of Biologics License Application (BLA) for Bevacizumab

Jun 07, 2021

Amneal Announces Dihydroergotamine (DHE) Autoinjector NDA for Migraines and Cluster Headaches

May 14, 2021

Amneal to Virtually Participate at Upcoming Investor Conferences

May 07, 2021

Amneal Reports First Quarter 2021 Financial Results

Apr 15, 2021

Amneal to Report First Quarter 2021 Results on May 7, 2021

Apr 05, 2021

Amneal Completes Acquisition of Kashiv Specialty Pharmaceuticals

Feb 26, 2021

Amneal Receives Approval for Generic Version of Ortho Evra®

Feb 26, 2021

Amneal Reports Fourth Quarter and Full Year 2020 Financial Results

Feb 22, 2021

Amneal to Virtually Participate at Upcoming Investor Conferences

Feb 04, 2021

Amneal to Report Fourth Quarter & Full Year 2020 Results on February 26, 2021

Jan 12, 2021

Amneal to Acquire Substantially All of Kashiv Specialty Pharmaceuticals

Jan 08, 2021

Amneal Launches Generic Abiraterone Acetate Tablets, USP, 500 mg, Following ANDA Approval by FDA

Jan 05, 2021

Amneal to Virtually Participate at the 39th Annual J.P. Morgan Healthcare Conference

© Amneal Pharmaceuticals LLC.

All rights reserved.

Powered By Q4 Inc. 5.66.0.1